Navigation Links
Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Date:11/16/2011

that its hemophilia B program was granted Orphan designation in the European Union.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law. 



'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... 10, 2014 Senior supply chain management ... associations, addressed the challenges of “Reducing Cost, Lead Time, ... through strategic sourcing. Describing the partnership of the Bio ... Chain Management Institute ( SCMI) of the University ... 24 at the Kroc Institute of Peace and Justice ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Pa., June 22 Environmental Tectonics Corporation,s (OTC Bulletin ... announced that the Japan Ministry of Health, Labor and ... foreign manufacturer in Japan. , , ETC worked ... to help ensure that our monoplace hyperbaric chambers passed ...
... , BERLIN, NIMES, France and RICHMOND, Calif., June ... company, Cezanne, and Lumiphore Inc., a biotechnology leader ... in high-value applications, announced that they have signed ... in BRAHMS diagnostic tests. , , ...
... NEW YORK, June 22 NeoStem, Inc. (NYSE Amex: ... storage of adult stem cells for future medical need, was featured ... Street," on June 18, 2009. Also, on June 16, 2009, ... in a substantial Fortune Magazine article distributed by CNNMoney.com. ...
Cached Biology Technology:Environmental Tectonics Corporation's BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 2Environmental Tectonics Corporation's BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 3Environmental Tectonics Corporation's BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 4BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 2BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 3NeoStem Featured in Business Week; 'Promising' Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article 2NeoStem Featured in Business Week; 'Promising' Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article 3NeoStem Featured in Business Week; 'Promising' Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article 4NeoStem Featured in Business Week; 'Promising' Adult Stem Cell Market Discussed in Fortune-CNNMoney.com Article 5
(Date:7/11/2014)... increased risk of kidney injury related to the use ... mass of HES molecules, according to a report in ... International Anesthesia Research Society (IARS). , The "total mass ... on cultured human renal proximal tubule cells (PTCs), concludes ... of University Hospital Wrzburg, Austria. Other factorssuch as ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2'Tailored' water -- the latest in lawn care 2
... ,Communication Intelligence Corporation (OTC Bulletin Board: CICI) ("CIC"),a ... process,automation in the financial industry and the recognized ... of Michael Betts to,the CIC Board of Directors. ... experience in the insurance and,financial services industries and ...
... McConnell, Director of,National Intelligence and James R. Clapper, ... valuable insights into the intelligence,challenges of the future, ... Community 100 Day Plan for INTEGRATION and COLLABORATION. ... the Director of National Intelligence and the National,Defense ...
... IdentiPHI announces the launch of SAFmodule(TM) 3.1 ... Services (NMAS) biometric authentication methods, AUSTIN, ... brings,secure, easily managed biometric authentication to Novell(R) ... with Novell,s,Novell Modular Authentication Service (NMAS(TM)) security ...
Cached Biology News:Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 3IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks 2
Medium for cryopreserving subcutaneous or omental preadipocytes...
... Exclusive ultra high yield technology is fast ... Amplifies aRNA for gene array analysis ... , Kits specific for templates ... promoters , All kits contain ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
Biology Products: